biostudies-literaturevan As NCancer Research UKAccurayNational Institute for Health Research (NIHR)1413-1425https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616714biostudies-literatureUnknown391(15)<h4>Background</h4>Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect to biochemical or clinical failure in patients with localized prostate cancer is unclear.<h4>Methods</h4>We conducted a phase 3, international, open-label, randomized, controlled trial. Men with stage T1 or T2 prostate cancer, a Gleason score of 3+4 or less, and a prostate-specific antigen (PSA) level of no more than 20 ng per milliliter were randomly assigned (in a 1:1 ratio) to receive SBRT (36.25 Gy in 5 fractions over a period of 1 or 2 weeks) or control radiotherapy (78 Gy in 39 fractions over a period of 7.5 weeks or 62 Gy in 20 fractions over a period of 4 weeks). Androgen-deprivation therapy was not permitted. The primary end point wThe New England journal of medicinePhase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.PMC7616714NIHR20331415955Kancherla Kvan As NLoblaw ATolan SArmstrong JBurnett SStaffurth JWells PGriffin CManning GTree AWilliamson EPugh JDayes IHall EPatel JJain SFrew JOstler PChu WChan ANaismith Ovan der Voet HCamilleri PMartin AFord DPrice DBrown SfalsePhase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.<h4>Background</h4>Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect to biochemical or clinical failure in patients with localized prostate cancer is unclear.<h4>Methods</h4>We conducted a phase 3, international, open-label, randomized, controlled trial. Men with stage T1 or T2 prostate cancer, a Gleason score of 3+4 or less, and a prostate-specific antigen (PSA) level of no more than 20 ng per milliliter were randomly assigned (in a 1:1 ratio) to receive SBRT (36.25 Gy in 5 fractions over a period of 1 or 2 weeks) or control radiotherapy (78 Gy in 39 fractions over a period of 7.5 weeks or 62 Gy in 20 fractions over a period of 4 weeks). Androgen-deprivation therapy was not permitted. The primary end point w2024-01-01T00:00:00Z2024 Oct2026-06-02T03:57:57.174Z2025-04-04T09:58:58.643ZS-EPMC76167143941337710.1056/NEJMoa2403365